Floatz logo

Zoledronate

Bone Neoplasms

AstraZenecaSmall moleculePhase 4 / ApprovedDormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Bone Neoplasms cohort.

Asset / SponsorPhaseRating
Irinotecan
Actuate Therapeutics Inc.
Phase 3BB
Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4BB
azd0530
AstraZeneca
Phase 2B
GEMOGENOVATUCEL-T
Gradalis, Inc.
Phase 3B
Inno-206
Actuate Therapeutics Inc.
Phase 2CCC

View all 16 →

Same molecule, other indications

Zoledronate is also rated in:

metastatic carcinoma in the boneDormant
BBB
Indicative ·
79 / 100
View asset →
osteoporosisDormant
BBB
Indicative ·
76 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →